Claritev (NYSE:CTEV) SVP William Mintz Sells 8,431 Shares

Claritev (NYSE:CTEV) SVP William Mintz sold 8,431 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $34.24, for a total value of $288,677.44. Following the transaction, the senior vice president owned 71,195 shares of the company’s stock, valued at approximately $2,437,716.80. This represents a 10.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Claritev Price Performance

Shares of NYSE:CTEV traded up $0.10 during midday trading on Wednesday, reaching $35.06. 125,661 shares of the company’s stock were exchanged, compared to its average volume of 164,896. The stock has a market cap of $597.70 million, a price-to-earnings ratio of -2.06 and a beta of 0.74. Claritev has a fifty-two week low of $11.50 and a fifty-two week high of $74.07. The firm’s 50 day simple moving average is $29.15 and its two-hundred day simple moving average is $23.83.

Wall Street Analyst Weigh In

CTEV has been the topic of a number of research analyst reports. Zacks Research lowered Claritev from a “hold” rating to a “strong sell” rating in a research report on Friday, July 17th. Citigroup reiterated a “buy” rating and issued a $45.00 price objective (up from $40.00) on shares of Claritev in a report on Monday. Barclays initiated coverage on Claritev in a research note on Friday, April 24th. They set an “overweight” rating and a $28.00 target price on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Claritev in a report on Wednesday, June 24th. Finally, Wells Fargo & Company lifted their target price on Claritev from $22.00 to $30.00 and gave the company an “equal weight” rating in a research report on Wednesday. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $42.83.

Institutional Investors Weigh In On Claritev

Hedge funds have recently added to or reduced their stakes in the business. Arini Captial Management Ltd purchased a new position in Claritev in the fourth quarter valued at $64,291,000. Beach Point Capital Management LP increased its holdings in Claritev by 77.4% during the 4th quarter. Beach Point Capital Management LP now owns 755,002 shares of the company’s stock worth $32,276,000 after purchasing an additional 329,424 shares during the period. AXQ Capital LP purchased a new stake in Claritev during the 4th quarter worth about $223,000. Hussman Strategic Advisors Inc. acquired a new stake in Claritev in the 4th quarter valued at about $449,000. Finally, Public Employees Retirement System of Ohio acquired a new stake in Claritev in the 1st quarter valued at about $38,000. 87.15% of the stock is currently owned by institutional investors and hedge funds.

Claritev Company Profile

Claritev is a healthcare technology, data and insights company focused on improving affordability,  transparency and quality. Led by deeply experienced associates, data scientists, and innovators, Claritev provides tech-enabled solutions and services fueled by multiple data sources from over 40 years of claims repricing. Claritev utilizes world-class technology and AI solutions to power a robust enterprise platform that delivers meaningful insights to drive affordability in healthcare, brings price transparency and optimizes networks and benefits design.